Genprex, Inc.
GNPXAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | May 17, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 4, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 3, 2024 |
Earnings History
Next report: Dec 2, 2026 · EPS est. $-6160.00| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-9.40 | — | — | — |
| May 13, 2026 | $-14.07 | — | — | — |
| Mar 30, 2026 | $-25.30 | $-286.00 | — | — |
| Nov 14, 2025 | $-109.89 | $-275.00 | — | — |
| Aug 8, 2025 | $-187.00 | $-15.62 | — | — |
| May 12, 2025 | $-285.71 | $-55.88 | — | — |
| Apr 1, 2025 | $-462.00 | $-18.04 | — | — |
| Nov 13, 2024 | $-1351.65 | $-1241.76 | — | — |
News
Whole-Blood Translational Analysis from Clinical Trial Patients Link TUSC2 to Mitochondrial Adaptation, Autophagy, and Protein Quality Control Expands Upon Existing REQORSA Research, Supporting Potential Beyond Oncology AUSTIN, Texas, Nov. 5, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, today announ…
Research to be Presented at the 2026 EORTC-NCI-AACR Symposium Links TROP2 Expression to Treatment Response and Explores its Role in Treatment Sensitivity Findings Suggest Low TROP2 Expression is Associated with Primary Resistance to REQORSA and May Help Guide Patient Selection AUSTIN, Texas, Nov. 4, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cance…
Research explores the role of TUSC2, the therapeutic gene used in Reqorsa® Gene Therapy in mitochondrial biology and cellular aging, supporting investigation of potential applications beyond oncology AUSTIN, Texas, Oct. 28, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, today announced that research c…
Collaborators publish new peer-reviewed study identifying sex-specific effects of TUSC2 loss on mitochondrial function, protein homeostasis, and synaptic pathways, alongside molecular similarities with human brain Findings suggest that TUSC2 may play a foundational role in brain health AUSTIN, Texas, Oct. 21, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor functio…
Company Presentation to Highlight Lead Clinical Oncology Program and Preclinical Diabetes Program AUSTIN, Texas, Sept. 8, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), today announced that members of its executive leadership team will present at and participate in the H.C.
Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials AUSTIN, Texas, Aug. 18, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading U.S. based clinical and commercial Contract …